Annual CFF
$53.99 M
+$9.97 M+22.66%
31 December 2023
Summary:
Armata Pharmaceuticals annual cash flow from financing activities is currently $53.99 million, with the most recent change of +$9.97 million (+22.66%) on 31 December 2023. During the last 3 years, it has risen by +$30.78 million (+132.61%). ARMP annual CFF is now at all-time high.ARMP Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$61.00 K
-$149.00 K-169.32%
30 September 2024
Summary:
Armata Pharmaceuticals quarterly cash flow from financing activities is currently -$61.00 thousand, with the most recent change of -$149.00 thousand (-169.32%) on 30 September 2024. Over the past year, it has dropped by -$24.87 million (-100.25%). ARMP quarterly CFF is now -100.14% below its all-time high of $44.63 million, reached on 31 March 2022.ARMP Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$34.91 M
-$24.87 M-41.60%
30 September 2024
Summary:
Armata Pharmaceuticals TTM cash flow from financing activities is currently $34.91 million, with the most recent change of -$24.87 million (-41.60%) on 30 September 2024. Over the past year, it has dropped by -$18.62 million (-34.78%). ARMP TTM CFF is now -41.60% below its all-time high of $59.78 million, reached on 30 June 2024.ARMP TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ARMP Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +22.7% | -100.3% | -34.8% |
| 3 y3 years | +132.6% | -170.9% | +84.6% |
| 5 y5 years | +333.6% | -100.0% | +63.0% |
ARMP Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +132.6% | -100.1% | +87.8% | -41.6% | +84.6% |
| 5 y | 5 years | at high | +501.5% | -100.1% | +87.8% | -41.6% | +289.0% |
| alltime | all time | at high | +1917.2% | -100.1% | +99.0% | -41.6% | +1275.2% |
Armata Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$61.00 K(-169.3%) | $34.91 M(-41.6%) |
| June 2024 | - | $88.00 K(-99.7%) | $59.78 M(+0.8%) |
| Mar 2024 | - | $34.93 M(<-9900.0%) | $59.33 M(+9.9%) |
| Dec 2023 | $53.99 M(+22.7%) | -$43.00 K(-100.2%) | $53.99 M(+0.9%) |
| Sept 2023 | - | $24.80 M(-6840.5%) | $53.53 M(+86.1%) |
| June 2023 | - | -$368.00 K(-101.2%) | $28.76 M(-0.8%) |
| Mar 2023 | - | $29.59 M(-6018.8%) | $28.98 M(-34.2%) |
| Dec 2022 | $44.02 M(+72.5%) | -$500.00 K(-1712.9%) | $44.02 M(-14.6%) |
| Sept 2022 | - | $31.00 K(-121.2%) | $51.55 M(-0.1%) |
| June 2022 | - | -$146.00 K(-100.3%) | $51.61 M(+0.1%) |
| Mar 2022 | - | $44.63 M(+534.1%) | $51.57 M(+102.1%) |
| Dec 2021 | $25.52 M(+9.9%) | $7.04 M(+8083.7%) | $25.52 M(+34.9%) |
| Sept 2021 | - | $86.00 K(-146.5%) | $18.91 M(+0.1%) |
| June 2021 | - | -$185.00 K(-101.0%) | $18.89 M(-2.5%) |
| Mar 2021 | - | $18.58 M(+4200.7%) | $19.38 M(-16.5%) |
| Dec 2020 | $23.21 M(+158.6%) | $432.00 K(+620.0%) | $23.21 M(+1.9%) |
| Sept 2020 | - | $60.00 K(-80.4%) | $22.78 M(+0.3%) |
| June 2020 | - | $306.00 K(-98.6%) | $22.72 M(-29.9%) |
| Mar 2020 | - | $22.41 M(>+9900.0%) | $32.39 M(+260.9%) |
| Dec 2019 | $8.97 M(-27.9%) | $0.00(0.0%) | $8.97 M(-58.1%) |
| Sept 2019 | - | $0.00(-100.0%) | $21.43 M(+42.6%) |
| June 2019 | - | $9.97 M(-1097.5%) | $15.02 M(+210.3%) |
| Mar 2019 | - | -$1.00 M(-108.0%) | $4.84 M(-61.1%) |
| Dec 2018 | $12.45 M(+43.6%) | $12.45 M(-294.4%) | $12.45 M(-6144.2%) |
| Sept 2018 | - | -$6.41 M(+3040.2%) | -$206.00 K(-103.7%) |
| June 2018 | - | -$204.00 K(-103.1%) | $5.59 M(-63.9%) |
| Mar 2018 | - | $6.61 M(-3308.7%) | $15.49 M(+78.6%) |
| Dec 2017 | $8.67 M(+20.0%) | -$206.00 K(-66.3%) | $8.67 M(-28.5%) |
| Sept 2017 | - | -$611.00 K(-106.3%) | $12.13 M(-4.7%) |
| June 2017 | - | $9.69 M(-4828.3%) | $12.73 M(+81.3%) |
| Mar 2017 | - | -$205.00 K(-106.3%) | $7.02 M(-2.8%) |
| Dec 2016 | $7.23 M(-43.5%) | $3.25 M(<-9900.0%) | $7.23 M(+82.0%) |
| Sept 2016 | - | -$17.00 K(-100.4%) | $3.97 M(-0.4%) |
| June 2016 | - | $3.99 M(>+9900.0%) | $3.99 M(+906.8%) |
| Mar 2016 | - | $0.00(0.0%) | $396.00 K(-96.9%) |
| Dec 2015 | $12.78 M(>+9900.0%) | $0.00(-100.0%) | $12.78 M(0.0%) |
| Sept 2015 | - | -$1000.00(-100.3%) | $12.78 M(-0.0%) |
| June 2015 | - | $397.00 K(-96.8%) | $12.78 M(+3.2%) |
| Mar 2015 | - | $12.38 M(>+9900.0%) | $12.38 M(>+9900.0%) |
| Dec 2014 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(-100.0%) |
| Sept 2014 | - | $0.00(0.0%) | $16.91 M(0.0%) |
| June 2014 | - | $0.00(0.0%) | $16.91 M(-32.1%) |
| Mar 2014 | - | $0.00(-100.0%) | $24.91 M(-3.8%) |
| Dec 2013 | $25.89 M(+2624.9%) | $16.91 M(>+9900.0%) | $25.89 M(+188.5%) |
| Sept 2013 | - | $0.00(-100.0%) | $8.97 M(0.0%) |
| June 2013 | - | $8.00 M(+719.5%) | $8.97 M(+819.5%) |
| Mar 2013 | - | $976.00 K(>+9900.0%) | $976.00 K(>+9900.0%) |
| Dec 2012 | $950.00 K(-466.8%) | - | - |
| Sept 2009 | - | $0.00(0.0%) | $0.00(-100.0%) |
| June 2009 | - | $0.00(0.0%) | -$258.00 K(0.0%) |
| Mar 2009 | - | $0.00(0.0%) | -$258.00 K(-0.4%) |
| Dec 2008 | -$259.00 K | $0.00(-100.0%) | -$259.00 K(-39.3%) |
| Sept 2008 | - | -$258.00 K(<-9900.0%) | -$427.00 K(-68.3%) |
| June 2008 | - | $0.00(-100.0%) | -$1.35 M(-108.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2008 | - | -$1000.00(-99.4%) | $16.56 M(-32.8%) |
| Dec 2007 | $24.63 M(+556.5%) | -$168.00 K(-85.7%) | $24.63 M(+3.3%) |
| Sept 2007 | - | -$1.18 M(-106.6%) | $23.85 M(-4.7%) |
| June 2007 | - | $17.91 M(+121.9%) | $25.03 M(+253.9%) |
| Mar 2007 | - | $8.07 M(-948.6%) | $7.07 M(+88.5%) |
| Dec 2006 | $3.75 M(-226.3%) | -$951.00 K(<-9900.0%) | $3.75 M(-19.7%) |
| Sept 2006 | - | $6000.00(-111.8%) | $4.67 M(+122.6%) |
| June 2006 | - | -$51.00 K(-101.1%) | $2.10 M(+6.2%) |
| Mar 2006 | - | $4.75 M(<-9900.0%) | $1.98 M(-166.5%) |
| Dec 2005 | -$2.97 M(-110.3%) | -$33.00 K(-98.7%) | -$2.97 M(-195.9%) |
| Sept 2005 | - | -$2.57 M(+1383.2%) | $3.10 M(-41.2%) |
| June 2005 | - | -$173.00 K(-13.1%) | $5.27 M(+1.1%) |
| Mar 2005 | - | -$199.00 K(-103.3%) | $5.21 M(-82.0%) |
| Dec 2004 | $28.97 M(+44.9%) | $6.04 M(-1640.1%) | $28.97 M(+27.5%) |
| Sept 2004 | - | -$392.00 K(+69.7%) | $22.72 M(-18.1%) |
| June 2004 | - | -$231.00 K(-101.0%) | $27.76 M(-36.7%) |
| Mar 2004 | - | $23.56 M(<-9900.0%) | $43.84 M(+119.2%) |
| Dec 2003 | $20.00 M(+99.9%) | -$210.00 K(-104.5%) | $20.00 M(-3.0%) |
| Sept 2003 | - | $4.64 M(-70.7%) | $20.62 M(+0.1%) |
| June 2003 | - | $15.85 M(-5642.3%) | $20.60 M(+105.8%) |
| Mar 2003 | - | -$286.00 K(-168.6%) | $10.01 M(+0.0%) |
| Dec 2002 | $10.01 M(-42.2%) | $417.00 K(-91.0%) | $10.01 M(-31.1%) |
| Sept 2002 | - | $4.62 M(-12.3%) | $14.51 M(-19.8%) |
| June 2002 | - | $5.26 M(-1926.7%) | $18.09 M(+20.5%) |
| Mar 2002 | - | -$288.00 K(-105.8%) | $15.01 M(-13.3%) |
| Dec 2001 | $17.32 M(-53.6%) | $4.93 M(-39.9%) | $17.32 M(+10.1%) |
| Sept 2001 | - | $8.19 M(+275.8%) | $15.73 M(+23.4%) |
| June 2001 | - | $2.18 M(+8.3%) | $12.75 M(+23.5%) |
| Mar 2001 | - | $2.01 M(-39.7%) | $10.32 M(-72.4%) |
| Dec 2000 | $37.36 M(+378.9%) | $3.34 M(-36.0%) | $37.36 M(+6.7%) |
| Sept 2000 | - | $5.21 M(-2230.1%) | $35.02 M(-3.0%) |
| June 2000 | - | -$244.80 K(-100.8%) | $36.10 M(-1.5%) |
| Mar 2000 | - | $29.05 M(+2804.9%) | $36.65 M(+369.9%) |
| Dec 1999 | $7.80 M(-39.5%) | $1.00 M(-84.1%) | $7.80 M(+2.6%) |
| Sept 1999 | - | $6.30 M(+2000.0%) | $7.60 M(+660.0%) |
| June 1999 | - | $300.00 K(+50.0%) | $1.00 M(-92.5%) |
| Mar 1999 | - | $200.00 K(-75.0%) | $13.40 M(+3.9%) |
| Dec 1998 | $12.90 M(-2680.0%) | $800.00 K(-366.7%) | $12.90 M(+8.4%) |
| Sept 1998 | - | -$300.00 K(-102.4%) | $11.90 M(0.0%) |
| June 1998 | - | $12.70 M(-4333.3%) | $11.90 M(-1290.0%) |
| Mar 1998 | - | -$300.00 K(+50.0%) | -$1.00 M(+100.0%) |
| Dec 1997 | -$500.00 K(-103.3%) | -$200.00 K(-33.3%) | -$500.00 K(+66.7%) |
| Sept 1997 | - | -$300.00 K(+50.0%) | -$300.00 K(-118.8%) |
| June 1997 | - | -$200.00 K(-200.0%) | $1.60 M(-89.0%) |
| Mar 1997 | - | $200.00 K(>+9900.0%) | $14.60 M(-2.7%) |
| Dec 1996 | $15.00 M(+18.1%) | $0.00(-100.0%) | $15.00 M(-3.8%) |
| Sept 1996 | - | $1.60 M(-87.5%) | $15.60 M(-40.5%) |
| June 1996 | - | $12.80 M(+2033.3%) | $26.20 M(+98.5%) |
| Mar 1996 | - | $600.00 K(0.0%) | $13.20 M(+3.9%) |
| Dec 1995 | $12.70 M(-3.1%) | $600.00 K(-95.1%) | $12.70 M(+5.0%) |
| Sept 1995 | - | $12.20 M(-6200.0%) | $12.10 M(<-9900.0%) |
| June 1995 | - | -$200.00 K(-300.0%) | -$100.00 K(-200.0%) |
| Mar 1995 | - | $100.00 K | $100.00 K |
| Dec 1994 | $13.10 M(+1537.5%) | - | - |
| Dec 1993 | $800.00 K | - | - |
FAQ
- What is Armata Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Armata Pharmaceuticals?
- What is Armata Pharmaceuticals annual CFF year-on-year change?
- What is Armata Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Armata Pharmaceuticals?
- What is Armata Pharmaceuticals quarterly CFF year-on-year change?
- What is Armata Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Armata Pharmaceuticals?
- What is Armata Pharmaceuticals TTM CFF year-on-year change?
What is Armata Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of ARMP is $53.99 M
What is the all time high annual CFF for Armata Pharmaceuticals?
Armata Pharmaceuticals all-time high annual cash flow from financing activities is $53.99 M
What is Armata Pharmaceuticals annual CFF year-on-year change?
Over the past year, ARMP annual cash flow from financing activities has changed by +$9.97 M (+22.66%)
What is Armata Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of ARMP is -$61.00 K
What is the all time high quarterly CFF for Armata Pharmaceuticals?
Armata Pharmaceuticals all-time high quarterly cash flow from financing activities is $44.63 M
What is Armata Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, ARMP quarterly cash flow from financing activities has changed by -$24.87 M (-100.25%)
What is Armata Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of ARMP is $34.91 M
What is the all time high TTM CFF for Armata Pharmaceuticals?
Armata Pharmaceuticals all-time high TTM cash flow from financing activities is $59.78 M
What is Armata Pharmaceuticals TTM CFF year-on-year change?
Over the past year, ARMP TTM cash flow from financing activities has changed by -$18.62 M (-34.78%)